Date | Acquired company | Acquiring company | Amount | Related | |
---|---|---|---|---|---|
2011-09-29 | Evotec's Joint Venture with DIL Limited (India) | Evotec (Germany) | €1.7 million | Drug discovery |
|
2011-09-28 | Novagali Pharma (France) | Santen Pharmaceutical (Japan) | €102 million | Ophtalmological diseases |
|
2011-09-27 | Newron (Italy) | Biotie Therapies (Finland) | €45 million | CNS diseases |
|
2011-09-26 | Teva-Kowa Pharma Co (Japan) | Teva Pharmaceuticals (Israel) | $150 million (€ 110.8 million) | Generic |
|
2011-09-06 | Biogen Dompé joint ventures in Italy and Switzerland | Biogen Idec (USA) | undisclosed | Neurodegenerative diseases |
|
2011-08-29 | Cellestis (Australia) | Qiagen (The Netherlands) | $374 million (€ 260 million) | ||
2011-08-26 | Bluefish Pharmaceuticals (Sweden) | BMM Pharma (Sweden) | € 4.16 million | Generic |
|
2011-08-22 | Microbiology Business of Biotest AG (Germany) | Merck KgaA (Germany) | undisclosed | microbiology |
|
2011-07-19 | Argene (France) | BioMérieux (France) | € 37.5 million with contingent payments of up to € 5 million | Molecular diagnostics |
|
2011-07-19 | mtm laboratories (Germany) | Roche (Switzerland) | Under the terms of the agreement, Roche will pay mtm shareholders an upfront payment of approximately €130 million (180 million USD) as well as up to approximately € 60 million (85 million USD) upon reaching performance-related milestones. | In vitro diagnostic |
|
2011-07-14 | Taiyo Pharmaceutical (Japan) | Teva Pharmaceuticals (Israel) | $934 million in cash | Generic |
|
2011-07-04 | Bioréalités (France) | Servier (France) | undisclosed | Cancer Oncology |
|
2011-06-30 | Cobra Biologics Holding AB (Sweden) | Recipharm AB’s shares in Recipharm Cobra Biologics (Sweden) | Manufacturing |
||
2011-06-15 | Ipsogen (France) | Qiagen (The Netherlands) | €70 million | Biomarkers |
|
2011-06-14 | Shenzhen GSK-Neptunus Biologicals Co. Ltd. (GSKNB) (China) | GSK (UK) | £24 million (€ 27 million - US$39 million) | Vaccines |
|
2011-06-01 | Compound Focus, Inc (compound management business of BioFocus, a Galapagos Company - USA-Belgium) | Evotec (Germany) | For the acquisition of all shares in Compound Focus Inc. Evotec will pay Galapagos an immediate cash upfront of €10.25M and an additional €2.25M in potential earn out payments upon performance of the business in 2012/2013 depending on revenues and certain corporate milestones. | Pharmaceutical development |
|
2011-05-24 | MitoSciences (USA) | Abcam (UK) | $6.0 million (£3.7 million - €4.25 million) | Mitochondrial research tools |
|
2011-05-24 | Prometheus Laboratories (USA) | Nestlé Health Sciences (Switzerland) | undisclosed | Diagnostic |
|
2011-05-19 | Phadia (Sweden) | Thermo Fisher Scientific (USA) | €2.47 billion | Allergy and Autoimmunity Diagnostics |
|
2011-05-19 | Nycomed (Switzerland) | Takeda Pharmaceutical (Japan) | € 9.6 billion | Gastroenterology |